HuLuc 63

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.


PDL BioPharma

XVIVO has produced several high quality animation videos for us and we will keep going back to them with future projects. This company provides exceptional customer service and has been a pleasure to work with.

Sr. Manager, New Products Marketing, Kinetic Concepts, Inc. (KCI)